Three months after researchers released a study of MSMs and transgender women that revealed a daily dose of Gilead's Truvada -- a combination of the AIDS drugs emtricitabine and tenofovir -- reduces the risk of contracting HIV, doctors say they are wary about giving healthy people a $12,000-a-year medicine that has side effects including nausea and kidney damage, and may not be used as regularly a